Tenofovir Rescue Therapy in Pregnant Females with Chronic Hepatitis B

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Mar 6

PMID 25741161

Citations 7

Authors

Yu-Hong Hu

Min Liu

Wei Yi

Yan-Jun Cao

Hao-Dong Cai

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the safety and efficacy of tenofovir monotherapy in pregnant females resistant to lamivudine or telbivudine. The effect of tenofovir on the fetus was also assessed.

Methods: The clinical data of 17 females were reviewed in this study. Adverse events and pregnancy outcomes from January 1, 2011 to June 30, 2013 were evaluated in the Department of Gynecology and Obstetrics of Beijing Ditan Hospital, Capital Medical University, Beijing, China. These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated.

Results: The median hepatitis B virus (HBV) DNA level in the pregnant females with LAM or LdT resistance was 5.9 (range, 4.2-7.2) log10 copies/mL before the initiation of TDF. Ten of these females had abnormal alanine aminotransferase (ALT) levels. The patients were treated with TDF for a median of 24 wk (range, 12-40 wk). Fourteen females (82.4%) had an HBV DNA level of <500 copies/mL at the time of delivery. This decrease was statistically significant (P<0.0001). Serum ALT levels were normalized in all subjects with an elevated serum ALT level at baseline (P=0.0003). There were no significant changes in serum creatinine and phosphorus levels during TDF treatment. In addition, no adverse events related to TDF treatment were observed. Seventeen females delivered 17 live infants, and all infants had good Apgar scores. The mean birth weight was 3226.5±331.7 g, and the mean length at birth was 50.4±1.1 cm. The growth and development of the infants was normal at birth, and no infants had birth defects related to TDF treatment. Eleven infants completed HBV vaccination and had no evidence of vertical transmission.

Conclusion: The use of TDF in pregnant females with chronic HBV and LAM or LdT resistance was safe and effective.

Citing Articles

Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.

Costa B, Gouveia M, Vale N Vaccines (Basel). 2024; 12(7).

PMID: 39066420 PMC: 11281481. DOI: 10.3390/vaccines12070782.

Treatment and prevention of viral hepatitis in pregnancy.

Dionne-Odom J, Cozzi G, Franco R, Njei B, Tita A Am J Obstet Gynecol. 2021; 226(3):335-346.

PMID: 34516961 PMC: 8907340. DOI: 10.1016/j.ajog.2021.09.002.

Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection.

Hu Y, Yu H Pediatr Investig. 2020; 4(2):133-137.

PMID: 32851357 PMC: 7331440. DOI: 10.1002/ped4.12205.

Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads.

Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N Sci Rep. 2018; 8(1):15514.

PMID: 30341345 PMC: 6195597. DOI: 10.1038/s41598-018-33833-w.

Current evidence on the management of hepatitis B in pregnancy.

Maraolo A, Gentile I, Buonomo A, Pinchera B, Borgia G World J Hepatol. 2018; 10(9):585-594.

PMID: 30310536 PMC: 6177570. DOI: 10.4254/wjh.v10.i9.585.

References

Vigano A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C . In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther. 2011; 16(8):1259-66. DOI: 10.3851/IMP1909. View

Liu M, Cai H, Yi W . Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat. 2013; 20 Suppl 1:65-70. DOI: 10.1111/jvh.12066. View

Abdelaziz T, Samir S . Congenital dislocation of the knee: a protocol for management based on degree of knee flexion. J Child Orthop. 2012; 5(2):143-9. PMC: 3058203. DOI: 10.1007/s11832-011-0333-7. View

Pol S, Corouge M, Fontaine H . Hepatitis B virus infection and pregnancy. Clin Res Hepatol Gastroenterol. 2011; 35(10):618-22. DOI: 10.1016/j.clinre.2011.03.013. View

Colbers A, Hawkins D, Gingelmaier A, Kabeya K, Rockstroh J, Wyen C . The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2012; 27(5):739-48. DOI: 10.1097/QAD.0b013e32835c208b. View

Lin C, Hsieh H, Huang Y, Huang Y, Ku M, Hung H . Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries. BMC Public Health. 2008; 8:49. PMC: 2275262. DOI: 10.1186/1471-2458-8-49. View

Reynaud L, Carleo M, Talamo M, Borgia G . Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag. 2009; 5(1):177-85. PMC: 2697525. DOI: 10.2147/tcrm.s3335. View

Lok A, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky J . Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46(1):254-65. DOI: 10.1002/hep.21698. View

Galluzzo C, Liotta G, Andreotti M, Luhanga R, Jere H, Mancinelli S . Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi. J Med Virol. 2012; 84(10):1553-7. DOI: 10.1002/jmv.23365. View

10.

Pan C, Lee H . Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis. 2013; 33(2):138-46. DOI: 10.1055/s-0033-1345718. View

11.

Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E . Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother. 2011; 56(2):857-62. PMC: 3264275. DOI: 10.1128/AAC.05244-11. View

12.

Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M . Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol. 2007; 46(2):754-6. PMC: 2238085. DOI: 10.1128/JCM.02142-07. View

13.

Liu C, Chang N, Chou P . Seroprevalence of HBV in immigrant pregnant women and coverage of HBIG vaccine for neonates born to chronically infected immigrant mothers in Hsin-Chu County, Taiwan. Vaccine. 2007; 25(44):7706-10. DOI: 10.1016/j.vaccine.2007.07.056. View

14.

Fung S, Lok A . Management of hepatitis B patients with antiviral resistance. Antivir Ther. 2005; 9(6):1013-26. View

15.

Liaw Y, Kao J, Piratvisuth T, Chan H, Chien R, Liu C . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2015; 6(3):531-61. DOI: 10.1007/s12072-012-9365-4. View

16.

Best B, Capparelli E . Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS. 2009; 3(3):277-82. PMC: 2804899. DOI: 10.1097/COH.0b013e3282f39f7e. View

17.

Pan C, Mi L, Bunchorntavakul C, Karsdon J, Huang W, Singhvi G . Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012; 57(9):2423-9. PMC: 7469074. DOI: 10.1007/s10620-012-2187-3. View

18.

Yi W, Liu M, Cai H . Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World J Gastroenterol. 2012; 18(45):6645-50. PMC: 3516809. DOI: 10.3748/wjg.v18.i45.6645. View

19.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

20.

Hoofnagle J, Doo E, Liang T, Fleischer R, Lok A . Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45(4):1056-75. DOI: 10.1002/hep.21627. View